ACE-536, a Novel, GDF-Trap, Promotes Rapid Increase of Red Blood Cells In Vivo in An EPO-Independent Manner.
Dianne Mitchell(Acceleron Pharma (United States)), Ravindra Kumar(Acceleron Pharma (United States)), Chris Rogers(Acceleron Pharma (United States)), Kathryn Underwood(Toronto Metropolitan University), June Liu(Capital Medical University), Kathleen Tomkinson(Acceleron Pharma (United States)), Samuel M. Cadena(Acceleron Pharma (United States)), Asya V. Grinberg(Dragonfly Therapeutics (United States)), R. Scott Pearsall(Acceleron Pharma (United States)), Joe Barberio(Acceleron Pharma (United States))
Cited by 0
Related Papers
ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension
|Science Translational Medicine|2020|240
Reduced Macrophage Apoptosis Is Associated With Accelerated Atherosclerosis in Low-Density Lipoprotein Receptor-Null Mice
|Arteriosclerosis Thrombosis and Vascular Biology|2004|219
Regulation of seminiferous tubule-associated stem Leydig cells in adult rat testes
|Proceedings of the National Academy of Sciences|2016|149
Perceptions of supportive communication in Chinese patients with cancer: experiences and expectations
|Journal of Advanced Nursing|2005|147
Vitamin E, aging and Leydig cell steroidogenesis
|Experimental Gerontology|2005|116